Related Experiment Video
Updated: Jun 8, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Antiproliferative effects of somatostatin analogs in endocrine tumours
1Section of Endocrinology, University of Ferrara Via Savonarola 9, 44100 Ferrara Italy.
Abstract:
Somatostatin has been discovered as a somatotroph release inhibitory factor (SRIF), and it has been demonstrated that SRIF and its analogs can inhibit hormone secretion and control the neoplastic bulk of several endocrine tumours. In vitro studies have contributed to the current knowledge of the mechanisms by which SRIF and its analogs may influence endocrine tumour proliferation, opening the way to new possible therapeutic strategies. Here, we focus on the studies concerning the antiproliferative effects of SRIF and its analogs that provide the basis for future investigations, both at basic and clinical levels, into the application of SRIF analogs in the endocrine field.
Insights
Somatostatin, also known as somatotroph release inhibitory factor (SRIF), and its analogs show promise in inhibiting hormone secretion and controlling endocrine tumors. Research into their antiproliferative effects supports future therapeutic applications in endocrinology.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Somatostatin (SRIF) is identified as a key inhibitor of growth hormone secretion.
- SRIF and its analogs exhibit inhibitory effects on hormone secretion and endocrine tumor growth.
Purpose of the Study:
- To review and synthesize in vitro findings on the antiproliferative mechanisms of SRIF and its analogs.
- To highlight the therapeutic potential of SRIF analogs in endocrine oncology.
Main Methods:
- Review of in vitro studies investigating SRIF and analog mechanisms.
- Analysis of data on hormone secretion inhibition and tumor bulk control.
Main Results:
- SRIF and its analogs demonstrate significant antiproliferative effects on endocrine tumor cells in vitro.
- These agents can modulate hormone secretion, suggesting a role in endocrine regulation.
Conclusions:
- In vitro evidence strongly supports the antiproliferative potential of SRIF analogs in endocrine tumors.
- Further basic and clinical research is warranted to explore SRIF analog applications in endocrine therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules